EUCAST and CLSI: Working together towards a harmonized method for antifungal susceptibility testing

Current Fungal Infection Reports

Volumn 7, Issue 1, 2013, Pages 59-67

  Espinel Ingroff, Ana ^a   Cuenca Estrella, Manuel ^b   Cantón, Emilia ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Amphotericin B; Aspergillus spp.; Candida spp.; CBPs; Clinical breakpoints; Clinical relevance; CLSI; Echinocandins; ECVs; Epidemiological cutoff values; EUCAST; Flucytosine; In vitro antifungal susceptibility testing; In vitro resistance; Moulds; Resistance molecular mechanisms; Triazoles; Yeasts

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; ASPERGILLUS VERSICOLOR; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CROSS RESISTANCE; CRYPTOCOCCUS; CRYPTOCOCCUS NEOFORMANS; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; FUNGUS MUTATION; HUMAN; INCUBATION TEMPERATURE; INTERMETHOD COMPARISON; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE;

EID: 84873727122     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-012-0125-7     Document Type: Article

References (54)

1. Garcia-Vidal C, Upton A, Kirby KA, et al. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47:1041-50.
2. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infections in adult hematopoietic stem cell transplant recipients: analysis of multicenter PATH Alliance Registry. Clin Infect Dis. 2009;48:265-73.
3. Meis JF, Chakrabarti A. Changing epidemiology of an emerging infection: zygomycosis. Clin Microbiol Infect. 2009;15 Suppl 5:10-4.
4. • Skiada S, Pagano L, Zimmerli S, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859-67. A recent report of the epidemiology of mucoral infections in Europe.
5. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. CLSI document M27-A3. 2008; Clinical and Laboratory Standards Institute. 940 West Valley Rd, Wayne, PA.
6. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; Informational Supplement, 3rd ed. CLSI document M27-S3. 2008; Clinical and Laboratory Standards Institute. 940 West Valley Rd, Wayne, PA.
7. Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed. Document M38-A2. Clinical and Laboratory Standards Institute 2008. 771 E. Lancaster Avenue, Wayne, Pennsylvania 19085.
8. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W, EUCAST-AFST. EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. Clin Microbiol Infect. 2012;18(7):E246-7. doi: 10.1111/j.1469-0691.2012.03880.x. Epub 2012 May 8. PubMed PMID: 22563750
9. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect. 2008;14:982-84.
10. • Espinel-Ingroff A. Mold in vitro susceptibility testing: is it ready for clinical practice? Int J Clin Rev. 2012;07:o6d0i: 5275/IJCR. This recent review describes in detail reference approaches for susceptibility testing of moulds; the clinical relevance of recently defined ECVs for Aspergillus spp. is provided.
11. • Espinel-Ingroff A, Cantón E, Pemán J. Antifungal susceptibility testing of filamentous fungi. 2012. Curr Fungal Infect Rep. 2012;6:41-50. This article describes standard and alternative methods for the susceptibility testing of filamentous fungi as well as available susceptibility cutoff values.
12. • Blum G, Perkhofer S, Haas H, et al. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother. 2008;52:1553-55. The basis for the intrinsic resistance of A. terreus to amphotericin B was investigated and it was concluded that catalase high levels may be the cause of resistance.
13. • Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009;15:1068-76. The higher incidence of azole resistance in Europe was reported.
14. van der Linden JW, Snelders E, Kampinga GA. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg Infec Dis. 2011;17:1846-54.
15. • Mavridou E, Bruggemann RJM, Melchers WJG, et al. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother. 2010;54:860-65. Higher posaconazole doses could be required for patients infected with posaconazole MICs of > 0.5 μg/ml; gene mutations were present.
16. Camps SMT, van der Linden JWM, Li Y, et al. Rapid Induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother. 2012;56:1-16.
17. Rocha EM, Garcia-Effron G, Park S, Perlin DS. A ser67Pro substitution in Fk51p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob Agents Chemother. 2007;51:4174-76.
18. • Walker LA, Gow NA, Munro CA. Fungal echinocandin resistance. Fungal Genet Biol. 2010;47:117-26. A summary of resistance mechanisms of echinocandins in Candida spp., and Aspergillus fumigatus is provided.
19. Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoam Micol. 2008;25:99-104.
20. Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resistance Updates. 2010;13:180-95. Adjusted fluconazole species-specific CBPs for Candida spp. are provided.
21. • Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diag Microbiol Infect Dis. 2011;70:330-43. Adjusted voriconazole species-specific CBPs for Candida spp. are provided.
22. • Pfaller, MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resistance Updates. 2011;14:164-76. Adjusted echinocandin species-specific CBPs for Candida spp. are provided.
23. • Arendrup MC, Cuenca-Estrella M. Donnelly JP, and the European committee on antimicrobial susceptibility testing-subcommittee on antifungal susceptibility testing. EUCAST technical note on posaconazole. Clin Microbiol Infect. 2011;17:E16-7. doi: 10.1111/j.1469-0691.2011.03646.x. Epub 2011 Sep 16. PubMed PMID: 21923779. EUCAST posaconazoleBPs for C. albicans and C. parapilosis are provided, which were not included in Table 2 of our paper.
24. • Arendrup MC, Rodriguez-Tudela J-L, Lass-Florl C, and the European committee on antimicrobial susceptibility testing-Subcommittee on antifungal susceptibility testing. EUCAST technical note on anidulafungin. Clin Microbiol Infect. 2011;17:E18-20. doi: 10.1111/j.1469-0691.2011.03647.x. Epub 2011 Sep 16. PubMed PMID: 21923778. EUCAST anidulafungin BPs for some common Candida spp. are provided.
25. • Lass-Florl C, Arendrup MC, Rodriguez-Tudela J-L, and the European committee 14. on antimicrobial susceptibility testing-Subcommittee on antifungal susceptibility testing (EUCAST-AFST). EUCAST technical note on amphotericin B. Clin Microbiol Infect. 2011;17:E27-9. doi: 10.1111/j.1469-0691.2011.03644.x. Epub 2011 Oct 19. PubMed PMID: 22011310. EUCAST BPs of amphotericin B for common Candida spp. are provided.
26. • Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect. 2012;18(7):E248-50. doi: 10.1111/j.1469-0691.2012.03890.x. Epub 2012 Apr 30. PubMed PMID: 22540149. EUCAST Breakpoints of amphotericin B, itraconazole and posaconazole for some Aspergillus spp. are provided.
27. •Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother. 2008;52:2468-72. EUCAST ECVs for A. fumigatus and the triazoles were provided in this article for the first time. Triazole cross-resistance was associated with specific cyp51A mutations.
28. • Espinel-Ingroff A, Diekema DJ, Fothergill A, et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2). J Clin Microbiol. 2010;48:3251-57. CLSI ECVs for six Aspergillus spp. and the triazoles were provided in this article.
29. • Espinel-Ingroff A, Fothergill A, Fuller J, et al. Wild-Type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:2855-59. CLSI ECVs for six Aspergillus spp. and caspofungin, which are not listed in Table 3 of our article, were provided in this article.
30. • Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, et al. Wild-Type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother. 2011;55:5150-54. CLSI ECVs for six Aspergillus spp. and amphotericin B were provided in this article.
31. Meletiadis J, Mavridou E, Melchers WJG, et al. Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis. Antimicrob Agents Chemother. 2012;56:2224-29.
32. • Jeans AR, Howard SJ, Al-Nakeeb Z, et al. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: Implications for in vitro susceptibility breakpoints. J Infect Dis Advance. 2012;206(3):442-52. BPs are suggested to test voriconazole and A. fumigatus using both CLSI and EUCAST methodologies.
33. • Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, et al. Cryptococcus neoformans- Cryptococcus gattii species complex: An international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother. 2012;56:3107-13. CLSI ECVs of amphotericin B and flucytosine were provided for this fungal group.
34. • Espinel-Ingroff A, Aller I, Canton E, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: An international study of Wild-Type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole and voriconazole. Antimicrob Agents Chemother. 2012;56:5898-906. CLSI ECVs of four triazoles were provided for this fungal group.
35. • Pfaller MA, Espinel-Ingroff A, Canton E, et al. Wild type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol. 2012;50:2040-46. CLSI ECVs of amphotericin B, flucytosine and itraconazole for Candida spp. were provided.
36. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.
37. Perfect JR, Dismukes WE, Francoise Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291-22.
38. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-60.
39. Alastruey-Izquierdo A, Cuenca-Estrella M. EUCAST and CLSI: how to assess in vitro susceptibility and clinical resistance. Curr Fungal Infect Rep. 2012;6:229-34.
40. Pfaller MA, Castanheira M, Jones RN. Advances in antifungal susceptibility testing of Candida, 2010-2012. Curr Fungal Infect Rep. 2012;6:141-53.
41. Pfaller MA, Boyken LB, Hollis RJ, et al. Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: Application of epidemiological cutoff values to results from a global Candida Antifungal Surveillance Program. J Clin Microbiol. 2011;49:1274-79.
42. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol. 2005;43:3884-9.
43. Rodriguez-Tudela JL, Donnelly JP, Pfaller MA, et al. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (EDef. 7.1) and CLSI (M27-A2). J Clin Microbiol. 2007;45:109-11.
44. Pfaller MA, Espinel-Ingroff A, Boyken LB, et al. Comparison of the broth microdilution (BMD) method of the European committee on antimicrobial susceptibility testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. J Clin Microbiol. 2011;49:845-50.
45. Cuenca-Estrella M, Lee-Yang W, Ciblak MA, et al. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob Agents Chemother. 2002;46:3644-7.
46. • Zaragoza O, Mesa-Arango AC, Gomez-Lopez A, et al. Process analysis of variables for standardization of antifungal susceptibility testing of nonfermentative yeasts. Antimicrob Agents Chemother. 2011;55:1563-70. EUCAST standard testing parameters for Cryptococcus spp. and other nonfermentative yeasts are proposed in this article.
47. Gomez-Lopez A, Aberkane A, Petrikkou E, et al. Analysis of the influence of tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp. Antimicrob Agents Chemother. 2005;43:1251-5.
48. • Dalhoff A, Ambrose PG, Mouton JW. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection. 2009;37:296-305. Definitions/differences between CBPs and ECVs are provided.
49. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother. 2009;53:112-22.
50. Garcia-Effron G, Lee S, Park S, et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-ß-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother. 2009;53:3690-9.
51. Turnidge J, Kahmeter G, Kronvall G. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect. 2006;12:418-25.
52. Park BJ, Arthington-Skaggs BA, Hajjeh RA, et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother. 2006;50:1287-92.
53. Verweij PE, Howard SJ, Melchers WJG, et al. Azole resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009;12:141-47.
54. Madureira A, Bergeron B, Claire Lacroixet C, et al. Breakthrough invasive aspergillosis in allogeneic hematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents. 2007;30:551-4.